Caribou Biosciences, Inc. (NASDAQ:CRBU) Given Average Rating of “Buy” by Analysts

Caribou Biosciences, Inc. (NASDAQ:CRBU) has been given a consensus rating of “Buy” by the five ratings firms that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $10.33.

Several brokerages recently weighed in on CRBU. Bank of America dropped their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Citigroup lowered their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th.

Caribou Biosciences Stock Performance

CRBU stock opened at $1.43 on Friday. The company has a market capitalization of $129.49 million, a PE ratio of -0.87 and a beta of 2.34. Caribou Biosciences has a one year low of $1.30 and a one year high of $8.33. The company’s 50 day moving average price is $1.77 and its two-hundred day moving average price is $1.98.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. On average, research analysts predict that Caribou Biosciences will post -1.64 EPS for the current year.

Institutional Trading of Caribou Biosciences

Several large investors have recently added to or reduced their stakes in CRBU. Milestone Asset Management LLC lifted its position in shares of Caribou Biosciences by 5.6% in the 4th quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock worth $260,000 after purchasing an additional 8,662 shares during the period. Thrive Wealth Management LLC purchased a new stake in Caribou Biosciences in the fourth quarter worth about $51,000. Green Alpha Advisors LLC boosted its position in Caribou Biosciences by 75.4% during the 4th quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock valued at $288,000 after acquiring an additional 77,840 shares in the last quarter. Barclays PLC grew its holdings in shares of Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after acquiring an additional 71,463 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Caribou Biosciences by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after acquiring an additional 124,782 shares in the last quarter. Institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.